311C90

The trigeminovascular system consists of bipolar neurons which innervate pain-sensitive intracranial structures and projecting to… Expand

311C90 (zolmitriptan zomig: (S)‐4[[3‐[2‐(dimethylamino)ethyl]‐1H‐indol‐5‐yl]methyl]‐2‐oxazolidinone) is a novel 5‐HT1B/1D… Expand

As shown in animal studies, 5HT1B/1D agonists can inhibit activity in the trigeminal nucleus caudalis, which may be advantageous… Expand

AIMS Two open studies in healthy volunteers were conducted to determine the absolute bioavailability and metabolic disposition of… Expand

&NA; Migraine is a common and debilitating condition. Its treatment has received considerable attention in recent times with the… Expand

311C90 is a novel, centrally and peripherally, acting 5-hydroxytryptamine (1D) receptor agonist. We investigated the efficacy and… Expand

1. 311C90 is a novel and selective agonist at 5-HT1D receptors, with central and peripheral actions, currently in development for… Expand

The oral absorption of a 10-m. oral dose of the novel 5-hydroxytryptamine (5HT1D) agonist, 311C90, was compared during a moderate… Expand

SYNOPSIS 

Migraine headache involves the activation of trigeminal afferents that are predominantly found in the first or ophthalmic… Expand